Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 4Genitourinary 3Thoracic 2Other solid neoplasm 2Lymphoid 2Tumor-Agnostic 1Sarcoma 1Other neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Metastatic Castration-Resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × sapanisertib × Genitourinary × Clear all
NCT03097328 2024-04-29

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
39 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT02091531 2019-11-21

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
9 enrolled 10 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03745911 2018-11-19

Paclitaxel and TAK-228 in Urothelial Carcinoma

Associació per a la Recerca Oncologica, Spain

Phase 2 Unknown
52 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡